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Abstract
Purpose Polar body (polar body) biopsy represents one pos-
sible solution to performing comprehensive chromosome
screening (CCS). This study adds to what is known about
the predictive value of polar body based testing for the genetic
status of the resulting embryo, but more importantly, provides
the first evaluation of the predictive value for actual clinical
outcomes after embryo transfer.
Methods SNP array was performed on first polar body, sec-
ond polar body, and either a blastomere or trophectoderm
biopsy, or the entire arrested embryo. Concordance of the
polar body-based prediction with the observed diagnoses in
the embryos was assessed. In addition, the predictive value of
the polar body -based diagnosis for the specific clinical out-
come of transferred embryos was evaluated through the use of
DNA fingerprinting to track individual embryos.
Results There were 459 embryos analyzed from 96 patients
with a mean maternal age of 35.3. The polar body-based
predictive value for the embryo based diagnosis was 70.3 %.
The blastocyst implantation predictive value of a euploid
trophectoderm was higher than from euploid polar bodies
(51 % versus 40 %). The cleavage stage embryo implantation
predictive value of a euploid blastomere was also higher than
from euploid polar bodies (31 % versus 22 %).
Conclusion Polar body based aneuploidy screening results
were less predictive of actual clinical outcomes than direct
embryo assessment and may not be adequate to improve
sustained implantation rates. In nearly one-third of cases the
polar body based analysis failed to predict the ploidy of the
embryo. This imprecision may hinder efforts for polar body
based CCS to improve IVF clinical outcomes.
Keywords Preimplantation genetic screening (PGS) . Polar
bodies . Aneuploidy . Blastocyst . SNP array
Introduction
Improving IVF outcomes is a critical focus of contemporary
reproductive medicine. Given the direct, causal relationship
between chromosomal aneuploidy and human pregnancy loss,
congenital birth defects, and IVF failure, there is great interest in
the clinical application of aneuploidy screening to improve IVF
outcomes. A validated single nucleotide polymorphism (SNP)
array-based technology was previously developed to compre-
hensively and accurately assess the chromosomal status of
embryos [1]. This technology has proven to be highly predictive
of the reproductive potential of human embryos [2] and has
demonstrated clinical efficacy in a randomized controlled trial
[3]. Alternate methods of comprehensive chromosome screen-
ing (CCS), including quantitative real-time PCR, have also been
developed and have yielded excellent outcomes in a retrospec-
tive study [4] and in randomized controlled trials [5, 6].
While there have been significant advances in screening
technologies, the question remains as to what stage in embry-
onic development, from the oocyte to the expanded blastocyst,
is the most appropriate for a biopsy to obtain DNA for aneu-
ploidy screening. Although all randomized controlled trials of
CCS reported to date have involved testing at the blastocyst
Capsule Although polar body based comprehensive chromosome
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stage of development [3, 5–7], polar body based aneuploidy
screening remains an option under consideration [8]. Through
examination of both polar bodies, it is possible to determine
whether the chromosomes segregated correctly during meio-
sis. Furthermore, polar body biopsy has been advocated as a
less invasive procedure than embryo biopsy [9], since polar
bodies are naturally extruded during development.
Given that maternal meiotic error is themajor contributor to
embryonic aneuploidy [10], the selective transfer of embryos
derived from oocytes that correctly segregated chromosomes
during meiosis has been hypothesized to improve clinical
outcomes [11]. In fact, the European Society of Human
Reproduction and Embryology (ESHRE) PGS Task Force
has launched a multicenter randomized controlled trial to
characterize the utility of polar body aCGH [12, 13]. However,
owing to the indirect nature of polar body based aneuploidy
screening, there is concern regarding its ability to accurately
predict the chromosomal status of the embryo [14–16] and its
reproductive potential. We sought to address these concerns
by comparing sequential biopsies of polar bodies and ensuing
embryos to determine the predictive value of polar body
testing for embryo ploidy and to perform a prospective blinded
nonselection analysis of the predictive value of polar body
based screening for delivery after embryo transfer.
Materials and methods
Population and ART cycles
The study population consisted of 96 couples attempting
assisted conception, in which the female partner was aged
24 to 42 years. The mean maternal age was 35.3±4.6 years
and the mean paternal age was 38.8±5.8 years. Cycles using
an oocyte donor were included and the age of the donor was
used. All patients were required to have a basal antral follicle
count of ≥8 and a serum day 3 FSH concentration of <12 IU/
L. Couples with 2 or more failed IVF cycles, i.e. no delivery
from the entire cohort of fresh and frozen embryos, were
excluded. Couples with a history of endometrial insufficiency,
chronic anovulation secondary to polycystic ovarian syn-
drome or with severe male factor infertility requiring surgical
sperm extraction were also excluded. Both partners were
required to have peripheral blood samples collected, which
allowed for isolation of parental DNA. The acquisition of
parental DNAwas necessary for accurate DNA fingerprinting
of the embryos and infants as previously described [17].
All patients underwent routine IVF stimulation, as deter-
mined by the patient’s primary physician. There were no
restrictions on the type of follicular stimulation used in the
study. All aspects of retrieval and oocyte recovery were per-
formed using established routine laboratory procedures and
have been previously reported [2].
Experimental design
The data in this investigation was extracted from a
nonselection study, which aimed to validate the accuracy of
DNA fingerprinting using polar bodies and embryonic cells.
The study was registered with ClincalTrials.gov under the
identifier NCT01219517. The specific study design has been
previously reported [2]. In short, all embryos in the study
underwent the same triple-biopsy procedure. Metaphase II
oocytes underwent first polar body biopsy following oocyte
retrieval and intracytoplasmic sperm injection (ICSI). At the
time of fertilization check the following morning, normally
fertilized oocytes with 2 pronuclei underwent a second polar
body biopsy. Finally, embryos were biopsied prior to transfer
on day 3 or day 5, as previously described [2]. Genetic results
were not available in time to influence the transfer decision
and there were no delays in the treatment schedule as a result
of this study.
Evaluating the karyotype of the embryo and polar bodies:
array-based aneuploidy screening
Polar body and blastomere or trophectoderm (TE) biopsies
were processed using SNP array based aneuploidy screening,
as previously described [1]. In short, cells were lysed in
alkaline solution and underwent whole genome amplification
using GenomePlexWGA4 (SigmaAldrich), followed by SNP
array-based analysis of copy number and genotypes using
NspI SNP genotyping arrays, copy number analysis tool,
and GTYPE software (Affymetrix) [2]. Resulting karyotype
predictions of the embryos and corresponding polar body
pairs were compared to determine the ability of polar body
based aneuploidy screening to predict embryo ploidy.
DNA fingerprinting to determine clinical outcomes
Parental genomic DNA was genotyped on the NspI array as
recommended by the supplier (Affymetrix) and used to iden-
tify informative SNPs for the conceptus, embryonic, and polar
body derived DNA, as previously described [17, 18]. Once the
genotype of the conceptus was known, the results were com-
pared with the genotype of the transferred embryos and the
corresponding polar bodies to determine which embryos im-
planted and progressed through delivery [17, 18].
Evaluating the predictive value of polar body-based
aneuploidy screening for embryo ploidy
Straightforward, descriptive statistics were applied to calcu-
late the predictive value of both polar bodies for embryo
ploidy. First, we predicted the chromosomal status of each
embryo based on the ploidy of its corresponding polar bodies.
When both polar bodies were euploid, the embryo was
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predicted to be euploid. When at least one polar body was
aneuploid, the embryowas predicted to be aneuploid. If one of
the two polar bodies failed to amplify or had no diagnosis and
the other was aneuploid, the embryo was defined as aneu-
ploid, despite not having a result in the other polar body.
Conversely, an embryo with one euploid polar body, but no
result in the other, was defined as unknown and excluded from
the predictive analysis. Embryos whose DNA failed to ampli-
fy or in which a karyotype prediction could not be accurately
made were excluded from the predictive analysis, along with
their corresponding polar bodies. The positive predictive val-
ue was calculated by dividing the sum of euploid polar body
outcomes corresponding to euploid embryos (true positives)
by the total number of euploid polar body outcomes (true
positives + false positives). The negative predictive value
was calculated by dividing the sum of aneuploid polar body
outcomes corresponding to aneuploid embryos (true nega-
tives) by the total number of aneuploid polar body outcomes
(true negatives + false negatives). The overall embryo ploidy
predictive value of both polar bodies was calculated by divid-
ing the sum of euploid polar bodies corresponding to euploid
embryos and aneuploid polar bodies corresponding to aneu-
ploid embryos by the total number of aneuploid and euploid
outcomes. The final results are expressed as a percentage.
Evaluating the predictive values of polar body-based
aneuploidy screening for clinical outcome
To calculate the predictive values of euploid and aneuploid
polar body-based aneuploidy screening results for clinical
outcome, we used identical methods to those previously de-
tailed for aneuploidy screening in embryo biopsy [2]. Briefly,
the outcomes for each embryo were determined. Embryos that
implanted and progressed through delivery were said to have a
successful outcome or a sustained implantation. All other
embryos, whether they failed to implant or resulted in a
biochemical or clinical loss, were considered to have failed.
The predictive value of an aneuploid result was calculated
by dividing the total number of embryos that had been desig-
nated as aneuploid by polar body based aneuploidy screening
and that failed to implant by the total number of embryos
transferred that had aneuploid polar body screening results
(aneuploid polar body failed/all with aneuploid polar bodies).
The predictive value of a euploid result was calculated by
dividing the number of predicted euploid embryos that had
sustained implantation by the total number of embryos that
were designated as having normal genetics by polar body
based aneuploidy screening (euploid polar body implanted/
all with euploid polar bodies). The results are expressed as a
percentage.
Additional analyses included evaluating the predictive
values of euploid and aneuploid screening results in polar
bodies from day 3 (cleavage-stage) embryo transfers as
opposed to those from day 5 (blastocyst-stage) transfers.
Finally, we compared the clinical predictive value for
sustained implantation from euploid and aneuploid polar body
based screening results to the predictive values obtained from
direct embryo based aneuploidy screening. Chi-squared anal-
yses were performed and an α-error of <0.05 was considered
significant for all comparisons.
Results
Reliability of obtaining a result
Ninety-six patients with a mean maternal age of 35.3±
4.6 years participated in this study. A total of 459 embryos
were evaluated. Nine (2 %) of the first polar body samples
failed to amplify and 10 (2 %) amplified but were nonconcur-
rent as previously defined [1]. Of the 440 (96 %) evaluable
first polar body array results, 330 (75%)were euploid and 110
(25 %) were aneuploid. Thirty two (7%) of second polar body
samples failed to amplify and 5 (1 %) amplified but were
nonconcurrent. Of the 422 (92 %) evaluable second polar
body array results, 320 (76 %) were euploid and 102 (24 %)
were aneuploid. Seventeen (4%) of the embryo samples failed
to amplify and 9 (2%) were nonconcurrent. Of the 433 (94%)
evaluable array results, 254 (59 %) were euploid and 179
(41 %) were aneuploid. Of the samples with discrepant polar
body and embryo biopsy diagnoses, there was not a general
pattern to characterize the discrepancies; i.e. some cases pre-
dicted an isolated monosomy, isolated trisomy, or complex
aneuploidy in an embryo with a euploid biopsy result. Failure
to obtain a result using a polar body approach was significant-
ly higher than direct testing of the embryo (12.2 % vs. 5.7 %;
RR 2.2, 95 % CI 1.4–3.4, P<0.001).
Predictive value for embryo ploidy
We next analyzed the level of agreement between polar body
and embryo based ploidy results. When both polar bodies
were euploid, the resulting embryo was euploid in 74.7 %
(174/233) of cases. When the array results from the polar
bodies predicted aneuploidy, 63.9 % (101/158) of embryos
were aneuploid. Incorporating both the negative and positive
predictive values, the overall predictive value of polar body-
based aneuploidy screening was determined to be 70.3 %.
Predictive value for implantation
Embryos with euploid first polar body and second polar body
had sustained implantation rates that were not significantly
higher than the overall cohort transferred without aneuploidy
screening (32 % vs. 23 %, P=0.16). In contrast, embryos with
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a euploid embryo biopsy had sustained implantation rates that
were significantly higher than the overall cohort transferred
without aneuploidy screening (42 % vs. 23 %, P=0.003). The
predictive value of a euploid embryo biopsy was higher than a
euploid polar body biopsy at each stage of transfer, with direct
analysis of trophectoderm having the highest predictive value
for delivery (Fig. 1).
Discussion
In theory, polar body CCS offers potential to improve patient
outcomes by reducing the time to pregnancy and the incidence
of miscarriage. However, the efficacy is contingent on the
ability to successfully predict the chromosomal status of the
embryo. The present work reveals that polar body aneuploidy
screening, using a method with 98.6 % diagnostic accuracy
[1], is limited in its ability to predict subsequent embryo
ploidy based upon consistency with blastomere and
trophectoderm analysis (70.3 %). Some prior studies which
assessed performance of polar body based screening only
compared results with ensuing whole embryos where aneu-
ploidy from post-zygotic mitotic errors would not be detected
[13, 19]. That is, evaluating the whole embryo would mask all
mitotic nondisjunction errors since the total number of chro-
mosomes within the entire embryo would be balanced. This
analysis strategy would therefore bias the results by only
detecting aneuploidy of meiotic origin, and favor finding a
correlation between the polar body and the embryo, since
polar bodies only allow detection of maternal meiotic errors.
In contrast, the present study evaluated cleavage-stage and
trophectoderm biopsies thus providing an opportunity to de-
tect aneuploidy derived from mitotic errors and providing a
more comprehensive assessment of all origins of embryonic
aneuploidy.
Several challenges associated with polar body testing itself
may result in the inability to predict the ploidy of the subse-
quent embryo. First, according to current practice, an embryo
is diagnosed as abnormal based on the observation of aneu-
ploidy in either polar body or in first polar body alone,
irrespective of whether the observed error is reciprocal [20,
21]. In cases of reciprocal aneuploidy, when a meiosis I error
due to premature separation of sister chromatids (PSSC) com-
pensates in meiosis II, the embryo should be disomic for the
reciprocal aneuploid chromosome. Isolated reciprocal aneu-
ploidies due to PSSC represent a potential source of misdiag-
nosis with polar body testing. Given that (i) reciprocal aneu-
ploidy is known to occur frequently in polar bodies observed
during human IVF [9, 22], (ii) PSSC is the predominant
mechanism of MI error [23, 24], and (iii) the delivery of a
healthy child has been documented from an oocyte with
reciprocal aneuploid polar bodies [25], the use of polar bodies
for aneuploidy screening raises immediate practical concerns,
as it may exclude embryos with true reproductive potential.
While the embryo ploidy predictive value of a euploid polar
body diagnosis (74.7 %) is superior to that of an aneuploid
diagnosis (63.9 %), it still implies that 1 in 4 embryos diag-
nosed as normal by polar body-based aneuploidy screening
will be aneuploid. This may limit its ability to improve IVF
outcomes. One source of this error is that polar body testing
can only evaluate the maternal contribution to aneuploidy.
Although the majority of embryonic aneuploidies are maternal
in origin, paternal and post-fertilization contributions are
Fig. 1 The sustained implantation
predictive value (with 95 %
confidence interval) of a euploid
screening result obtained from the
first polar body (PB1), PB1 and the
second polar body (PB2), or a
direct embryo biopsy for each stage
of embryo transfer (cleavage-stage
and blastocyst stage)
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estimated to account for about 10 % of embryonic abnormal-
ities in clinical miscarriages [10] and possibly a higher propor-
tion of preimplantation embryos that fail to implant [26–28].
The findings of the present work differ from data published
by Geraedts et al. in the preclinical study of polar body aCGH
for prediction of zygote ploidy [13]. The ESHRE aneuploidy
screening Task Force aCGH data indicated an aneuploid polar
body result was 94 % predictive of the ploidy status of the
zygote [13]. However, the aCGH methodology used had not
been evaluated for accuracy in predicting aneuploidy from
single cells with previously characterized karyotypes. In con-
trast, the present study involved an independent CCS platform
utilizing a validated, WGA and SNP array technology [1, 3,
29]. SNP array data reveals an aneuploid polar body diagnosis
is only 63.9 % predictive of embryo ploidy. Several factors
may account for this discrepancy, including the fact that the
ESHRE study tested early zygotes before the cleavage stage of
development when mitotic errors might occur.
Other reasons for divergent findings from the ESHRE
study may relate to study size. The present analysis includes
381 paired polar body and embryo samples, which exceeds
the sample size of the ESHRE analysis (138 oocyte/polar
body pairs) [13]. Differences between each study’s patient
populations also must be considered. The mean maternal age
in the current investigation is 35.3 +/− 4.6, while the ESHRE
study evaluated patients with an average age of 40 [13]. Most
significantly, Geraedts et al. reported an overall embryonic
aneuploidy rate of 76%, whereas we report an aneuploidy rate
of only 41 %.
The present study indicates that polar body aneuploidy
screening has limited ability to predict embryo ploidy. How-
ever, it remains to be seen if this level of accuracy is sufficient
to improve IVF clinical outcomes. The sample size of embry-
os transferred with known reproductive outcome did not dem-
onstrate a significant improvement when using polar body-
based screening compared with transferring the entire cohort
had it been unscreened. A euploid result on direct embryo
biopsy, on the contrary, would result in a significant improve-
ment in sustained implantation rates. The positive predictive
values in Fig. 1 suggest that trophectoderm biopsy of the
blastocyst may be the optimal stage in embryonic develop-
ment for aneuploidy screening.
A normal result with trophectoderm biopsy is known to be
more predictive of a positive clinical outcome than blastomere
biopsy [2]. Even more, it has been shown that blastomere
biopsy significantly impairs embryonic reproductive potential
while trophectoderm biopsy does not [30]. The current study
evaluates polar body testing as a proposed alternative, but
concludes that polar body testing is limited by imprecision.
Lending strong support to this conclusion, a recent study
assessing the optimal biopsy stage for aneuploidy screening
found testing at the polar body stage to be least accurate, due
to the high-incidence of post-zygotic events [15]. Furthermore,
another study using aCGH found a 12% false positive rate when
comparing predicted aneuploid chromosomes in the polar bodies
to whole embryos, despite the lack of ability to detect differences
from mitotic derived aneuploidies [16]. In addition to reduced
predictive value, our data also indicate reduced reliability of
obtaining a diagnosis, with a 12.2 % no result rate when testing
2 polar bodies per embryo, as compared to a 5.7 % no result rate
with embryo biopsy alone. Therefore, the final realization of
benefit from aneuploidy screening may require trophectoderm
biopsy at the blastocyst-stage.
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